期刊
JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY
卷 24, 期 5, 页码 900-911出版社
WILEY
DOI: 10.1111/j.1440-1746.2008.05668.x
关键词
gamma delta-T cell; adoptive cell therapy; innate antitumor immunity; intercellular adhesion molecule (ICAM)-1 (CD54); ICAM-2 (CD102); pancreatic cancer
gamma delta-T cells can recognize and kill malignant cells, particularly those of epithelial origin, through mechanisms which do not require the recognition of tumor-specific antigens (innate immune response). This natural ability of gamma delta-T cells to kill tumor cells in a tumor antigen-independent manner provides a strong rationale for developing clinical trials designed to exploit the innate antitumor properties of gamma delta-T cells. In vitro studies were carried out to asses the sensitivity of pancreatic cancer cells (MIA PaCa2, BxPC-3, PANC-1) to killing by ex vivo expanded human gamma delta-T cells. The capacity of gamma delta-T cells to bind to as well as to kill pancreatic cancer cells correlated with the degree of surface expression of key intercellular adhesion molecules (ICAM) present on pancreatic cancer cells. Moreover, pancreatic cancer cells expressing neither ICAM-1 nor ICAM-2 were bound poorly by gamma delta-T cells and were found to be resistant to gamma delta-T-cell killing. However, upon transfection of resistant cells with ICAM-1 or ICAM-2, gamma delta-T cells were then able to bind to and subsequently kill these cells. In vitro, the expression of ICAM-1 or ICAM-2 on human pancreatic cancer cells is critically important in determining the extent to which these cells are sensitive to killing by human gamma delta-T cells. Accordingly, in ongoing and future clinical studies using gamma delta-T cells for the treatment of a variety of epithelial-derived solid tumors-including pancreatic cancer-interventions intended to modulate ICAM expression on tumor cells may become important adjuncts to gamma delta-T-cell-based immunotherapies.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据